ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01221077
Recruitment Status : Completed
First Posted : October 14, 2010
Last Update Posted : October 13, 2014
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : March 2013
  Actual Study Completion Date : September 2014
  Certification/Extension First Submitted : February 20, 2014